Another CD22-CAR T, SCRI-CAR22v2, is being tested in a phase 1/2 multicenter clinical trial, PLAT-07, in pediatric and young adult patients with R/R CD22+ leukemia or lymphoma (NCT04571138). Here, CD22 is linked to lymphoma.